#immunemonitoring

The global ELISpot and fluorospot assay market size was estimated at USD 311.8 million in 2024 and is projected to grow at a CAGR of 6.3% from 2025 to 2030. This growth can be attributed to the rising incidences of chronic and infectious diseases, increasing drug discovery activities, rising adoption in research and diagnostics, and expanding pre-clinical and clinically regulated bioanalysis. The ELISpot and fluorospot assays are used to access immune responses, increasing their importance in understanding the effect of various diseases on the immune system, including cancer.

ELISpot and Fluorospot assay are used to detect and characterize naturally occurring tumor-reactive T-cells, which serve as suitable mediators of cancer immunotherapy. Moreover, these assays are also being used for epitope mapping, identification of tumor antigens, and monitor vaccine-induced T and B-cell responses. Moreover, the development of hepatocellular carcinoma (HCC) and cervical cancer is closely linked to high-risk infections with human papillomavirus (HPV) and hepatitis B virus (HBV), respectively. Tumor-specific vaccines are frequently tested in animal models and cell lines; for example, the HPV vaccine was assessed in mice and cell lines using the IFN-γ and IL-2 ELISPOT assay.

Detection of antigen-specific T cell responses via the IFN-γ ELISPOT assay in a patient with metastatic cervical cancer aids researchers in developing new treatment strategies. Researchers are working to halt cancer progression by inducing tumor-specific cytotoxic T lymphocytes (CTLs) through dendritic cells loaded with tumor DNA or tumor homogenate. Another approach involves generating virus-vectored genetic vaccines, such as using an Adenovirus vector encoding tumor antigens. The response of tumor-specific CTLs can be determined by the ELISPOT assay.

For More Details or Sample Copy please visit link @: ELISpot And Fluorospot Assay Market

Key ELISpot And Fluorospot Assay Company Insights

Some key companies operating in the market include BD; U-CyTech; Cellular Technology Limited; Mabtech; Abcam Limited; Autoimmun Diagnostika GmbH; among others. Organizations are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services, such as expansion activities and partnerships are playing a key role in propelling market growth.

U-CyTech specializes in ELISA and ELISpot assays, offering T and B cell solutions for ex vivo detection of protein-secreting cells. They develop specific monoclonal and polyclonal antibodies enhancing assay sensitivity and reliability for immunology research and diagnostics.